동아ST

We will continue to strive for global new drug development.

NEWS

No Subject Date View
22

Dong-A ST, Accord launch Stelara biosimilar Imuldosa in US

2025-11-14 43
21

Dong-A ST, SK bioscience, and Onconic Therapeutics are among 7 Innovative Pharmaceutical Companies

2025-01-08 590
20

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

2025-01-08 576
19

CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to STELARA®

2024-10-23 846
18

US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

2024-10-23 614
17

Dong-A ST's ECG Monitoring Platform Hicardi+ H100 Receives U.S. FDA Approval

2024-09-30 523
16

Dong-A ST and its subsidiary to codevelop long-acting obesity drug with ImmunoForge

2024-08-20 594
15

Dong-A ST Presents Preclinical Results of Tau-Targeting Dementia Treatment ‘DA-7503’ at AAIC

2024-08-08 969
14

DA-1241 Global Phase 2 Part 1 Patient Recruitment Completed

2024-04-05 811
13

Dong-A ST, STGen Bio, ST Pharm's Triangular Partnership at Songdo Bio Hub

2024-04-05 1580